| BackgroundMyocardial regeneration ability is very limited, at the present stage,cardiac tissue engineering and stem cell biology of the latest progress to restore the function of the myocardial injury have brought great hope and new therapeutic strategies. Nowadays, in all available for myocardium transplant seed cells, the adipose tissue-derived mesenchymal stem cells(ADMSCs) has become a research hotspot because its convenience and sufficient source. ADMSCs is a heterogeneous cell group, and the most current studies was aimed at the impure ADMSCs. There are few reports for research on purification of ADMSCs in vitro, therefore the clinical application of ADMSCs has been limited. As a result, it is necessary to purify ADMSCs and study its biological characteristics of different subsets, which can help to improve the relevance and effectiveness of cell therapy research.ObjectiveTo examine the different results of the treatment of MI with grafring of CD73+ADMSCs and CD73-ADMSCs and unpurified ADMSCs in rats, so that experimental reference for treatment of myocardial ischemia could be offered.Methods1. Isolation, culture and identification of ADMSCs of mouse, Passage to the third generation, the use of flow cytometry selected CD73+and CD73-ADMSCs two subpopulations, using flow cytometry to select the two subpopulations of CD73+ADMSCs and CD73-ADMSCs for assessment of biological characteristics and the ability to differentiation of myocardium after the passage to the third generation.2. To establish the model of myocardial infarction by ligation of the left anterior descending branch in SD rats. The use of ECG and histological techniques to identify the model of myocardial infarction.3. Directly to inject CD73+ADMSCs, CD73"ADMSCs and unpurified ADMSCs into the myocardium of model rats which labeled with DAPI, then to observe the capillary density and the status of angiogenesis in the different groups1week,2week,3week and4week later.Results1. Four weeks after transplantation, group CD73+ADMSCs left ventricular ejection raction(LVEF)(70.60±1.91)%, left ventricular fraction shortening (LVFS)(63.53±2.12)%have obvious enhancement (P<0.05) compare with group ADMSCs and CD73"ADMSCs LVEF(66.42±3.19,61.38±3.17)%,LVFS (33.87+1.59,30.72+2.75)%. Left ventricular end diastolic diameter(LVDd) of group CD73+ADMSCs (6.11+0.31)mm have dramatic decline (P<0.05) compare with group ADMSCs and CD73-ADMSCs (6.58±0.38,6.59±0.49)mm. That suggest the CD73+ADMSCs grafting is better to improve the myocardial systolic function.2. We found that CD73+ADMSCs can increase blood capillary density and promote angiogenesis by the examination of vascular endothelial growth factor(VEGF) and Ⅷ factor with IHC and Western blotting.ConclusionsCD73+ADMSCs is expected to become one of the most application prospect of myocardial cell therapy because it can effectively improve cardiac remodeling and improve cardiac function by their high potential to differentiate into myocardium and more effectively promote angiogenesis. |
PDF Full Text Request